Contact us for more information: **info@pulmonxstratx.com**

pulmonX®

www.pulmonx.com

Pulmonx International Sàrl
Rue de la Treille 4
2000 Neuchâtel, Switzerland
Tel: +41 32 475 20 70
Fax: +41 32 475 20 71

Pulmonx Corporation
700 Chesapeake Drive
Redwood City, CA 94063 USA
Tel: +1 (650) 364-0400

REFERENCES:
[1] Klooster et al. N Engl J Med, 373;24, 2015. / [2] Koster TD, et al. Predicting Lung Volume Reduction after Endobronchial Valve Therapy Is Maximized Using A Combination of Diagnostic Tools. Respiration 2016 (in press). / [3] Reymond et al. AJR: 201, October 2013.

CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.
CAUTION: The StratX Lung Analysis Platform is not available in the US.

D0231EN_A

StratX™

Lung Analysis Platform

TREAT WITH **CONFIDENCE**

pulmonX®

StratX™

Lung Analysis Platform

A cloud-based quantitative CT analysis service that supports endobronchial valve (EBV) patient selection and treatment targeting by providing clinically-validated information on emphysema destruction, fissure completeness and volume

> **Pulmonx EBV treatment is the most rigorously studied minimally-invasive treatment for severe emphysema and is proven to improve patients' breathing function, exercise capacity and quality of life.[1]**

90%

Accuracy

in identifying EBV responders and non-responders when combined with selective use of the Chartis Pulmonary Assessment System[2]

Easy to Identify Patients Most Likely to Benefit

from EBV treatment

Clinically-Validated and Consistent

across scanners and hospitals[2]



SUMMARY
Illustration summarizes key information

RESULTS
Table lists validated measurements by lobe:

- Fissure completeness
- Emphysema density (based on voxel density less than -910 HU)
- Inspiratory volume

USER-FRIENDLY DESIGN

for clear interpretation and ease of use

CLINICALLY-VALIDATED ALGORITHM

for fissure completeness

The StratX analysis quantifies the completeness of each fissure using an algorithm that has been validated in a retrospective study of over 200 EBV patients, the largest such analysis performed to date.[2] Fissure completeness is a proven predictor for volume reduction resulting from EBV therapy.[3]

	RIGHT LUNG			
	RUL	RUL+RML	RML	RLL
% Fissure Completeness	64.2	65.0	84.9	65.0

OPTIMAL APPROACH

The StratX analysis combined with selective use of the Chartis system results in higher accuracy than when either diagnostic tool is used alone.[2]

1. Assess all potential EBV patients with the StratX analysis.
2. For patients in which the StratX analysis identified partially complete fissures, proceed with a Chartis assessment.
3. Patients with complete fissures or identified with the Chartis assessment as CV- can receive EBV therapy.



StratX Analysis

Complete Fissures
(>95% complete)

Partially Complete Fissures
(80-95% complete)

Incomplete Fissures
(<80% complete)

EBV Therapy



Chartis Assessment

CV-

CV+

Do Not Treat with EBV Therapy

WORKFLOW WITH RAPID TURNAROUND TIME

1

Capture CT Scan

Capture a high resolution chest CT scan according to the StratX CT parameters.

2

Upload CT Scan

Use web browser to upload CT scan to the secure, cloud-based StratX platform.

- Automatically anonymized data with no patient health information transfer
- Secure 256 bit SSL socket level encryption



3

Analyze Data + Generate Report

Data is analyzed by validated algorithms and the StratX report is uploaded to the StratX platform within 2-3 working days.

4

Review Report

Access pulmonxstratx.com to review the report in a .pdf (2D) or .html (3D) format from any clinical setting.

5

Confidently Determine Treatment Options

Determine the most suitable treatment option for your patient using the quantitative StratX information and clinical judgment.